Held by 5 specialist biotech funds
High Convergence# Signal Note: Driehaus Capital Initiates $111.9M Wave Life Sciences Position Driehaus's entry into WVE signals conviction in Wave's antisense platform, likely driven by momentum in its lead program WVE-004 for CHARGE syndrome (a rare genetic disorder affecting ~1 in 10,000 births), which entered Phase 2 in 2024. The $111.9M stake positions Driehaus to benefit from near-term clinical readouts and potential rare disease label expansion, given Wave's pipeline breadth across CNS and genetic indications where antisense has shown clinical utility. This move reflects growing institutional confidence in second-generation antisense as a differentiated modality versus first-gen competitors.
+ 3more — see how much conviction went in
See the Full Story